Infiniplex

Infiniplex is a deep-tech precision oncology company based in Israel developing advanced liquid biopsy solutions that enable rapid, sensitive, and accessible cancer mutation detection. Its core platform, InfiniplexDX, combines proprietary molecular-switch PCR primer chemistry with algorithmic signal deciphering to detect mutations down to 0.01% variant allele frequency across multiple clinically relevant cancer biomarkers in a single workflow. The platform is designed to run on standard PCR infrastructure already available in labs worldwide, eliminating the need for expensive sequencing equipment and making frequent, actionable molecular testing feasible throughout the patient journey. Infiniplex targets five priority clinical indications and aims to close the actionability gap in cancer care by delivering treatment-guidance insights within hours.